AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated ...

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum- …

AstraZeneca's lung cancer trial success hailed by broker

AstraZeneca PLC (LSE:AZN) has scored another significant milestone in its cancer treatment programme, securing accelerated approval from the US Food and Drug Administration (FDA) for Datroway, a promising drug aimed at treating advanced lung cancer. …

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For Type Of Lung Cancer

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s AZN Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior …

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo’s Datroway (Datopotamab deruxtecan) for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). …

AstraZeneca's Datroway gets green light from FDA

AstraZeneca said the indication was approved under accelerated approval based on objective response rate and duration of response. However, it said continued approval may be contingent upon verification and description of clinical benefits in a …

AstraZeneca's Datroway receives FDA approval, Rio Tinto announces Hancock Prospecting JV

STOCKS TO WATCH Drugmaker AstraZeneca's Datroway has been approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer. AstraZeneca said the indication was approved under accelerated approval based on …

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a subset of non-small cell lung cancer (NSCLC) patients. The antibody drug conjugate has …

US approves AstraZeneca, Daiichi’s treatment for lung cancer

(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this indication and expanding access for patients. …

FDA approves AstraZeneca, Daiichi Sankyo's Datroway in EGFR-mutated lung cancer

The World Can’t Wait: Delivering on the Promise of Biopharma’s “Golden Age” Mina Makar, Senior Vice President, Global ...

This year’s BIO International Convention drew thousands of innovators, policymakers, patients and advocates from across the globe to Boston—a fitting backdrop for what feels like an inflection point in the trajectory of life sciences in the US and around …